DeepNewz, mobile.

People-sourced. AI-powered. Unbiased News.

Screenshot of DeepNewz app showing story detail view.

Screenshot of DeepNewz app showing story list view.

European Hematology Association News

Phase III Trials Show Pola-R-GemOx Extends Median OS to 19.5 Months, Zanubrutinib 36-Month PFS 67.4%, Glofitamab Cuts Progression Risk by 59% in Lymphomas

Phase III Trials Show Pola-R-GemOx Extends Median OS to 19.5 Months, Zanubrutinib 36-Month PFS 67.4%, Glofitamab Cuts Progression Risk by 59% in Lymphomas

5

2 months ago

Latest stories

Jun 19, 2025
Jun 19, 2025
Health
Pharma
Science
Phase III Trials Show Pola-R-GemOx Extends Median OS to 19.5 Months, Zanubrutinib 36-Month PFS 67.4%, Glofitamab Cuts Progression Risk by 59% in Lymphomas
Authors
5
2 months ago

Join our channels

Get the latest stories live on any device.

WhatsApp
Top Stories
Join
Telegram
Top Stories
Join